Exelixis (EXEL) Tops Q2 EPS by 7c ; Offers Guidance
Tweet
Share
E-mailGet Alerts EXEL Hot Sheet
Price: $57.67 -2.27%
Revenue Growth %: +8.8%
Financial Fact:
Research and development: 22.98M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +8.8%
Financial Fact:
Research and development: 22.98M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Exelixis (NASDAQ: EXEL) reported Q2 EPS of $0.91, $0.07 better than the analyst estimate of $0.84. Revenue for the quarter came in at $628.69 million versus the consensus estimate of $633.8 million.
GUIDANCE:
Exelixis sees FY2026 revenue of $2.5-2.55 billion, versus the consensus of $2.6 billion.
For earnings history and earnings-related data on Exelixis (EXEL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Braze, Inc. (BRZE) Tops Q2 EPS by 4c; offers guidance
- BMO Capital Starts Steven Madden (SHOO) at Outperform
- ServiceTitan, Inc. (TTAN) Misses Q2 EPS by 1c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
